Application of proteomics in diabetes and its complications

TAO Yingjun; WU Jie; LIU Chang

doi:10.11665/j.issn.1000-5048.20200315

Journal of China Pharmaceutical University > 2020 > 51(3): 368-373. > DOI: 10.11665/j.issn.1000-5048.20200315

TAO Yingjun, WU Jie, LIU Chang. Application of proteomics in diabetes and its complications[J]. Journal of China Pharmaceutical University, 2020, 51(3): 368-373. DOI: 10.11665/j.issn.1000-5048.20200315

Citation:

PDF (780 KB)

Application of proteomics in diabetes and its complications

Funds: This study was supported by the National Natural Science Foundation of China ( No. 81673340)

More Information

Received Date: October 29, 2019
Revised Date: May 10, 2020

Graphical Abstract

Abstract

Abstract

Proteomics is one of the most advanced fields and hotspots in the research of various diseases in recent years. Its development has provided a new research direction for the early diagnosis and treatment of diabetes and has achieved some research results. Early diagnosis is helpful to control the progression of the disease or even avoid surgical treatment, which is of great significance for improving the prognosis of patients. This paper reviews the current status and prospects of proteomic technology and its applications in diabetes as well as its complications with a prospect of the impact of the rapid development of proteomics on diabetes and its positive role in discovering more diabetes biomarkers. In the future research, more attention should be paid to the interconnections between biomarkers.
- proteomics,
- diabetes,
- diabetic complications,
- early diagnosis,
- biomarker

FullText(HTML)

References (39)

References

[1]	. Wiley Interdiscip Rev Syst Biol Med， 2019， 11（5）： e1450.
[2]	Vaudel M， Barsnes H， R?der H， et al. Using proteomics bioinformatics tools and resources in proteogenomic studies［J］. Adv Exp Med Biol， 2016， 926： 65-75.
[3]	Joubert R， Strub JM， Zugmeyer S， et al. Identification by mass spectrometry of two-dimensional gel electrophoresis-separated proteins extracted from lager brewing yeast［J］. Electrophoresis， 2001， 22（14）： 2969-2982.
[4]	Chen GD， Pramanik BN. Application of LC/MS to proteomics studies： current status and future prospects［J］. Drug Discov Today， 2009， 14（9/10）： 465-471.
[5]	Cs?sz， Deák E， Kalló G， et al. Diabetic retinopathy： proteomic approaches to help the differential diagnosis and to understand the underlying molecular mechanisms［J］. J Proteomics， 2017， 150： 351-358.
[6]	Haythorne E， Rohm M， van de Bunt M， et al. Diabetes causes marked inhibition of mitochondrial metabolism in pancreatic β-cells［J］. Nat Commun， 2019， 10（1）： 2474.
[7]	Mohan V， Radha V. Precision diabetes is slowly becoming a reality［J］. Med Princ Pract， 2019， 28（1）： 1-9.
[8]	Wang Y， An HY， Liu T， et al. Metformin improves mitochondrial respiratory activity through activation of AMPK［J］. Cell Rep， 2019， 29（6）： 1511-1523.e5.
[9]	Khan RMM， Chua ZJY， Tan JC， et al. From pre-diabetes to diabetes： diagnosis， treatments and translational research［J］. Medicina （Kaunas）， 2019， 55（9）： E546.
[10]	Metz TO， Qian WJ， Jacobs JM， et al. Application of proteomics in the discovery of candidate protein biomarkers in a diabetes autoantibody standardization program sample subset［J］. J Proteome Res， 2008， 7（2）： 698-707.
[11]	Zhang QB， Fillmore TL， Schepmoes AA， et al. Serum proteomics reveals systemic dysregulation of innate immunity in type 1 diabetes［J］. J Exp Med， 2013， 210（1）： 191-203.
[12]	Soggiu A， Piras C， Bonizzi L， et al. A discovery-phase urine proteomics investigation in type 1 diabetes［J］. Acta Diabetol， 2012， 49（6）： 453-464.
[13]	Huth C， von Toerne C， Schederecker F， et al. Protein markers and risk of type 2 diabetes and prediabetes： a targeted proteomics approach in the Kora F4/FF4 study［J］. Eur J Epidemiol， 2019， 34（4）： 409-422.
[14]	Lietzén N， Hirvonen K， Honkimaa A， et al. Coxsackievirus B persistence modifies the proteome and the secretome of pancreatic ductal cells［J］. iScience， 2019， 19： 340-357.
[15]	Lutty GA. Effects of diabetes on the eye［J］. Invest Ophthalmol Vis Sci， 2013， 54（14）： ORSF81.
[16]	Rangasamy S， McGuire PG， Das A. Diabetic retinopathy and inflammation： novel therapeutic targets［J］. Middle East Afr J Ophthalmol， 2012， 19（1）： 52-59.
[17]	Whitehead M， Osborne A， Widdowson PS， et al. Angiopoietins in diabetic retinopathy： current understanding and therapeutic potential［J］. J Diabetes Res， 2019， 2019： 5140521.
[18]	Jin J， Min H， Kim SJ， et al. Development of diagnostic biomarkers for detecting diabetic retinopathy at early stages using quantitative proteomics［J］. J Diabetes Res， 2016， 2016： 6571976.
[19]	Torok Z， Peto T， Csosz E， et al. Tear fluid proteomics multimarkers for diabetic retinopathy screening［J］. BMC Ophthalmol， 2013， 13（1）： 40.
[20]	Hirao Y， Saito S， Fujinaka H， et al. Proteome profiling of diabetic mellitus patient urine for discovery of biomarkers by comprehensive MS-based proteomics［J］. Proteomes， 2018， 6（1）： E9.
[21]	Campion CG， Sanchez-Ferras O， Batchu SN. Potential role of serum and urinary biomarkers in diagnosis and prognosis of diabetic nephropathy［J］. Can J Kidney Health Dis， 2017， 4： 2054358117705371.
[22]	Yoon JJ， Park JH， Kim HJ， et al. Dianthus superbus improves glomerular fibrosis and renal dysfunction in diabetic nephropathy model［J］. Nutrients， 2019， 11（3）： E553.
[23]	Thippakorn C， Schaduangrat N， Nantasenamat C. Proteomic and bioinformatic discovery of biomarkers for diabetic nephropathy［J］. EXCLI J， 2018， 17： 312-330.
[24]	de Boer IH， Rue TC， Cleary PA， et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria： an analysis of the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort［J］. Arch Intern Med， 2011， 171（5）： 412-420.
[25]	Son MK， Yoo HY， Kwak BO， et al. Regression and progression of microalbuminuria in adolescents with childhood onset diabetes mellitus［J］. Ann Pediatr Endocrinol Metab， 2015， 20（1）： 13-20.
[26]	van JA， Scholey JW， Konvalinka A. Insights into diabetic kidney disease using urinary proteomics and bioinformatics［J］. J Am Soc Nephrol， 2017， 28（4）： 1050-1061.
[27]	Moresco RN， de Carvalho JAM. Applying proteomics to diagnosis of diabetic kidney disease［J］. Expert Rev Proteomics， 2017， 14（10）： 841-843.
[28]	Harpole M， Davis J， Espina V. Current state of the art for enhancing urine biomarker discovery［J］. Expert Rev Proteomics， 2016， 13（6）： 609-626.
[29]	Papale M， di Paolo S， Vocino G， et al. Proteomics and diabetic nephropathy： what have we learned from a decade of clinical proteomics studies［J］？ J Nephrol， 2014， 27（3）： 221-228.
[30]	Wende AR. Post-translational modifications of the cardiac proteome in diabetes and heart failure［J］. Proteomics Clin Appl， 2016， 10（1）： 25-38.
[31]	Dewey S， Sohal M， Gomes AV. Proteomic analysis of Akita mice reveals 9 proteins altered during early stages of diabetic cardiomyopathy［J］. Biophys J， 2013， 104（2）： 313a-314a.
[32]	Pai YW， Lin CH， Lin SY， et al. Reconfirmation of newly discovered risk factors of diabetic peripheral neuropathy in patients with type 2 diabetes： a case-control study［J］. PLoS One， 2019， 14（7）： e0220175.
[33]	Hosseini A， Abdollahi M. Diabetic neuropathy and oxidative stress： therapeutic perspectives［J］. Oxid Med Cell Longev， 2013， 2013： 168039.
[34]	Zhang TJ， Gao YB， Gong YB， et al. Tang-Luo-ning improves mitochondrial antioxidase activity in dorsal root Ganglia of diabetic rats： a proteomics study［J］. Biomed Res Int， 2017， 2017： 8176089.
[35]	Singh A， Subramani E， Datta Ray C， et al. Proteomic-driven biomarker discovery in gestational diabetes mellitus： a review［J］. J Proteomics， 2015， 127（Pt A）： 44-49.
[36]	Kim SM， Park JS， Norwitz ER， et al. Identification of proteomic biomarkers in maternal plasma in the early second trimester that predict the subsequent development of gestational diabetes［J］. Reprod Sci， 2012， 19（2）： 202-209.
[37]	Seyhan AA， Carini C. Are innovation and new technologies in precision medicine paving a new era in patients centric care ［J］？J Transl Med， 2019， 17（1）： 114.
[38]	Vitzthum F， Behrens F， Anderson NL， et al. Proteomics： from basic research to diagnostic application. A review of requirements & needs［J］. J Proteome Res， 2005， 4（4）： 1086-1097.
[39]	Colhoun HM， Marcovecchio ML. Biomarkers of diabetic kidney disease［J］. Diabetologia， 2018， 61（5）： 996-1011.

[1]	WANG Shihao, LIU Lifeng, DING Yang, LI Suxin. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 522-529. DOI: 10.11665/j.issn.1000-5048.2024011902
[2]	BAI Yan, GUO Xinyao, QIN Qiliang, YAN Fang. Advances in research on mechanism of lactate dehydrogenase B in tumors[J]. Journal of China Pharmaceutical University, 2023, 54(2): 172-179. DOI: 10.11665/j.issn.1000-5048.20221112001
[3]	XING Xuyang, WANG Xiaochun, HE Wei. Advances in research on tumor immunotherapy and its drug development[J]. Journal of China Pharmaceutical University, 2021, 52(1): 10-19. DOI: 10.11665/j.issn.1000-5048.20210102
[4]	LI Fang, XIN Junbo, SHI Qin, MAO Chengqiong. Advances in near infrared photoimmunotherapy of tumor[J]. Journal of China Pharmaceutical University, 2020, 51(6): 664-674. DOI: 10.11665/j.issn.1000-5048.20200604
[5]	FENG Yang, XU Xiao, MO Ran. Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406
[6]	TANG Keqin, LIN Huaqing, LI Shuhong, DONG Lixin, LU Bohong, JIANG Hong. Advances in tumor targeted nanocrystals[J]. Journal of China Pharmaceutical University, 2020, 51(4): 418-424. DOI: 10.11665/j.issn.1000-5048.20200405
[7]	LI Haoxian, LIN Huaqing, CHEN Jingwen, WANG Liyuan. Research progress of carbon nanomaterials in cancer drug delivery[J]. Journal of China Pharmaceutical University, 2019, 50(1): 100-106. DOI: 10.11665/j.issn.1000-5048.20190114
[8]	DONG Hong, WU Ruixue, LIU Jiaqi, HUANG Qing, ZHOU Ya, HU Yiqiao. Advances in cancer photodynamic therapy[J]. Journal of China Pharmaceutical University, 2016, 47(4): 377-387. DOI: 10.11665/j.issn.1000-5048.20160401
[9]	SUN Zhan-yi, CAI Hui, HUANG Zhi-hua, SHI Lei, CHEN Yong-xiang, LI Yan-mei. Advances of glycopeptide-associated tumor vaccines[J]. Journal of China Pharmaceutical University, 2012, 43(2): 97-106.
[10]	YANG Li, YOU Qi-dong, YANG Yong, GUO Qing-long. Research advances in wogonin′s anti-tumor effects[J]. Journal of China Pharmaceutical University, 2009, 40(6): 576-579.

Cited By

Get Citation

PDF

XML

Article views (333) PDF downloads (567)

Turn off MathJax

Article Contents

Abstract

References

Application of proteomics in diabetes and its complications

Abstract

References

Related Articles

Catalog

Application of proteomics in diabetes and its complications

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content